Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Aug 8;11(9):ofae460.
doi: 10.1093/ofid/ofae460. eCollection 2024 Sep.

Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma

Jessica S Little  1   2   3 , Rocio M Hurtado  2   4 , Nicholas Boire  2   5 , Lindsey R Baden  1   2   3 , Alvaro C Laga  2   5 , Ann W Silk  2   6 , Caron A Jacobson  2   3
Affiliations

Disseminated Mycobacterium avium Complex Infection Following CD3/CD20 Bispecific Antibody Therapy in a Patient With Follicular Lymphoma

Jessica S Little et al. Open Forum Infect Dis. .

Abstract

Infections remain a major concern following bispecific antibody therapy but are not well described in pivotal trials. We present the first well-documented case of a classic but rare opportunistic infection, disseminated Mycobacterium avium complex, in a patient receiving bispecific antibody therapy.

Keywords: bispecific antibody therapy; disseminated Mycobacterium avium complex infection; immunotherapy; opportunistic infection.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest: A.W.S. reports receiving grants/research support (to the institution) from Replimune, Morphogenesis, Regeneron, and Merck, fees from Natera, Merck, Regeneron, and Leerink, royalties from UpToDate, Inc, and stock ownership in Illumina, Inc. C.J. reports consulting/advisory role for AbbVie, Abintus Bio, ADC Therapeutics, BMS/Celgene, Caribou Bio, Daiichi Sankyo, ImmPACT Bio, Instil Bio, Ipsen, Kite, a Gilead Company, Miltenyi Biotec, MorphoSys, Novartis, and Synthekine, and research funding from Kite, a Gilead Company and Pfizer. The remaining authors declare no competing interests.

Figures

Figure 1.
Figure 1.
Positron emission tomography/computed tomography prior to treatment (A) and following treatment (C) and histopathologic findings (B) of disseminated Mycobacterium avium complex infection in a patient following bispecific antibody therapy.
Figure 2.
Figure 2.
Timeline of disseminated Mycobacterium avium complex infection in a patient following bispecific antibody therapy.
See this image and copyright information in PMC

References

    1. Teh BW, Mikulska M, Averbuch D, et al. Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients. Lancet Infect Dis 2024; 24:e59–68. - PubMed
    1. Raje N, Anderson K, Einsele H, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J 2023; 13:116. - PMC - PubMed
    1. Klein C, Brinkmann U, Reichert JM, Kontermann RE. The present and future of bispecific antibodies for cancer therapy. Nat Rev Drug Discov 2024; 23:301–19. - PubMed
    1. Longhitano AP, Slavin MA, Harrison SJ, Teh BW. Bispecific antibody therapy, its use and risks for infection: bridging the knowledge gap. Blood Rev 2021; 49:100810. - PubMed
    1. Cliff ERS, Reynolds G, Popat R, Teh BW, Kesselheim AS, Mohyuddin GR. Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma. J Clin Oncol 2023; 41:1949–51. - PubMed